Fig. 1: Inhibition of hypusination limits CRC cell growth in vitro.
From: Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation
a Proliferation assay in HT29 (n = 3), HCT116 (n = 3), SW480 (n = 3), and LoVo (n = 3) cells treated with different concentrations of GC7 (0.1, 1, 10, 50, and 100 μM) for 24, 48, and 72 h (upper panels). b Cell viability assay (MTT) (n = 3) of HCT116 treated for 48 h with 100 μM GC7, 200 μM DFMO, 10 μM Cisplatin, or control vehicle. c Western blot analysis of full-length and cleaved PARP, tubulin (loading control) in HCT116 cells treated with 100 μM GC7, 200 μM DFMO, 10 μM Cisplatin, or control vehicle for 48 h. d Flow cytometry analysis (n = 3) of HCT116 cells stained with annexin V after 24 h from treatments with 100 μM GC7, 200 μM DFMO, 10 μM Cisplatin, or control vehicle. e Cell cycle profile (n = 3) of HCT116 cells treated with 100 μM GC7, 200 μM DFMO, 10 μM Cisplatin, or control vehicle for 24 h. f Left, HCT116 cells were infected with lentiviruses expressing DHPS (shDHPS) or control (SCR) shRNAs for 72 h. After infection, cells were incubated with 100 μM GC7 and counted at the indicated time points or treated with 100 μM GC7 for 48 h and MTT assay performed (middle). Right, western blotting showing DHPS, Hyp-EIF5A, EIF5A, and Vinculin (loading control) levels before treatment. g Left, HCT116 cells were infected with lentiviruses expressing EIF5A (shEIF5A) or control (SCR) shRNAs for 72 h. After infection, cells were incubated with 100 μM GC7 and counted at the indicated time points or treated with 100 μM GC7 for 48 h and MTT assay performed (middle). Right, western blotting showing EIF5A, Hyp-EIF5A, and Vinculin (loading control) levels before treatment. For statistical analysis: ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, by one-way ANOVA. Data represent the mean ± SD of experiments performed in triplicates and repeated at least three times.
